In addition to identifying small molecules that selectively block the Gαi-GIV interaction and that can act intracellularly, assessing their possible impact on normal physiological functions linked to GIV and/or Gαi will be crucial to further pursue this target in the context of cancer experimental therapeutics. The gene discussed is CCDC88A; the disease is cancer.